Treatment of Genital, Scalp and Face Psoriasis with Risankizumab

Psoriasis affecting the face, scalp, hands, feet, nail and genitals may cause disproportional impact on quality of life despite the small surface area compromised. Genital psoriasis can affect 33 to 63% of psoriasis patients at any time during their lives. Even though GenPs is relatively common, these lesions may be under-reported and under diagnosed because of embarrassment of patients, unfamiliarity with the disease or concerns about having a sexually transmitted disease. Several effective treatments have been reported for plaque psoriasis, however there are few studies and reports regarding GenPs treatment. We report here a case of successful treatment of a patient with genital, face and scalp psoriasis with risankizumab, an anti-IL23 drug

Clinical evidence of therapy for genital psoriasis by biologic agents

Data in the scientific literature on the use of biologic therapy in localized forms of psoriasis elucidate mostly the problems of treatment of palmoplantar, scalp psoriasis and nail psoriasis. At the same time, the number of scientific data on the effect of biological therapy on genital psoriasis is extremely limited. Important that the quality of life on patients with genital psoriasis has very low level, which indicates a significant influence on the psychological and social well-being. At the same time, the limited number of therapeutic approaches makes this problem even more urgent. Unfortunately, special clinical trials for such patients are rather an exception. Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis. New data on the comparative efficacy of ixekizumab and secukinumab give hope us for new opportunity for the treatment of genital psoriasis.

Genital psoriasis: Update on clinical practices and therapeutic options

Psoriasis is a chronic skin disease with an important inflammatory compound which associates a worldwide prevalence of 0.5% to 8.5%. The involvement of the genital region can be associated with both plaque psoriasis and inverse psoriasis and survey-based studies indicate that up to 45.5% of patients present lesions of genital psoriasis. Genital psoriasis represents a frequent encounter of psoriasis which is often overlooked and which associates a significant impact on their quality of life, measured by Dermatology Life Quality Index (DLQI) scores which are twice as high as those of psoriatic patients without genital involvement. Recognising the specific clinical findings represents an important step in establishing the diagnosis and case management. Classical therapeutic options such as topical steroids or modern treatments such as ixekizumab represent important tools in fighting this affliction and regaining the patient’s quality of life. This review aims to emphasize the up-to-date clinical variants of genital psoriasis, the consequences on the quality of life of patients and to present the newest therapeutic options.